Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (X-PLORE)
This study is ongoing, but not recruiting participants.
Study NCT01483599   Information provided by Janssen Inc.

First Received on November 29, 2011.   Last Updated on May 6, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Psoriasis
More general conditions related to this trial
Skin Diseases
Skin Diseases, Papulosquamous
Interventions listed in this trial
CNTO 1959 (5 mg)
CNTO 1959 (15 mg)
CNTO 1959 (50 mg)
CNTO 1959 (100 mg)
CNTO 1959 (200 mg)
Adalimumab
Placebo to CNTO 1959 (100 mg)
More general drug interventions related to this trial
Anti-Inflammatory Agents
Antirheumatic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Janssen Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services